Target intelligence / Profile preview

Tricarboxylate transport protein, mitochondrial (SLC25A1)

Target
SLC25A1
Molecular classification
Transporter, Mitochondrial carrier protein, Solute carrier family
01

Overview

Tricarboxylate transport protein, mitochondrial (SLC25A1) is a mitochondrial inner membrane transporter protein that exchanges citrate (from the mitochondrial matrix) for malate (from the cytosol)[1][3]. This carrier plays a central role in cellular metabolism by exporting mitochondrial citrate, a precursor for fatty acid and cholesterol biosynthesis, and regulating key metabolic processes including glycolysis and energy production[1][3]. SLC25A1 is essential for maintaining cytosolic acetyl-CoA levels and NADPH generation via the citrate–malate shuttle. Mutations in SLC25A1 disrupt this exchange, leading to combined D,L-2-hydroxyglutaric aciduria, an inborn error of metabolism with prominent neurological symptoms resulting from abnormal organic acid accumulation and impaired energy metabolism[1][3]. SLC25A1 is part of the larger mitochondrial carrier family (SLC25), whose members share structural features and a common transport mechanism across the mitochondrial inner membrane[2]. Altered SLC25A1 activity or expression has also been implicated in cancer metabolic reprogramming and possibly other diseases[3].

Other names
SLC25A1Tricarboxylate carrier proteinCitrate transport proteinCICCTPCMS23D2L2ADSEASLC20A3Mitochondrial citrate carrierCitrate–isocitrate carrierSolute carrier family 25 member 1
02

Mechanism of action

Inhibition of mitochondrial citrate export; disruption of cellular acetyl-CoA and lipid synthesis; modulation of metabolic flux between mitochondria and cytosol

03

Biological functions

Mitochondrial citrate/malate transportCellular energy metabolismLipid (fatty acid) biosynthesisRegulation of glycolysis
04

Disease associations

Metabolic disease (e.g., combined D,L-2-hydroxyglutaric aciduria)CancerNeurometabolic disorderDevelopmental disorder
05

Safety considerations

Potential disruption of energy metabolism and lipid synthesisrisk of neurological deficits due to impaired mitochondrial metabolite transportoff-target metabolic toxicity
06

Interacting drugs

None currently approved specifically targeting SLC25A1; experimental small-molecule inhibitors and research chemicals (e.g., CTPI-2, BTA) are noted in the literature but not in clinical use
07

Biomarkers

Elevated D-2-hydroxyglutarate and L-2-hydroxyglutarate in plasma/CSF (for combined D,L-2-hydroxyglutaric aciduria)potentially SLC25A1 expression/mutation status in cancer metabolic profiling

Beyond the preview

Go deeper on Tricarboxylate transport protein, mitochondrial (SLC25A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tricarboxylate transport protein, mitochondrial (SLC25A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call